[1]
|
Yu, N., Wang, S., Song, X., et al. (2018) Low-Dose Radiation Promotes Dendritic Cell Migration and IL-12 Production via the ATM/NF-κB Pathway. Radiation Research, 189, 409-417. https://doi.org/10.1667/RR14840.1
|
[2]
|
李静. 银屑平丸对银屑病样小鼠模型血清中IL-4和IL-12表达水平的影响[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2022. https://doi.org/10.27138/d.cnki.ghuzc.2022.000411
|
[3]
|
张良芬, 吴勤学, 王群. 银屑病患者血清中细胞因子状态的研究[J]. 中华皮肤科杂志, 2001, 34(2): 101-102.
|
[4]
|
Quatrini, L.,Vacca, P., Tumino, N., et al. (2021) Glucocorticoids and the Cytokines IL-12, IL-15, and IL-18 Present in the Tumor Microenvironment Induce PD-1 Ex-pression on Human Natural Killer Cells. Journal of Allergy and Clinical Immunology, 147, 349-360. https://doi.org/10.1016/j.jaci.2020.04.044
|
[5]
|
Naoya, K., Shohei, K., Shin, H., et al. (2022) Walls Teichoic Ac-id-Dependent Phagocytosis of Intact Cell Walls of Lactiplantibacillus plantarumwall Elicits IL-12 Secretion from Mac-rophages. Frontiers in Microbiology, 13, Article 986396. https://doi.org/10.3389/fmicb.2022.986396
|
[6]
|
Kaveh, A., Karen, L., Mehrnoosh, A., Elizabeth, M.H., Larry, L., Nevil, J. and Eric, O. (2022) Dendritic Cells Trigger IFN-γ Secretion by NK Cells Independent of IL-12 and IL-18. European Journal of Immunology, 52, 1431-1440.
https://doi.org/10.1002/eji.202149733
|
[7]
|
Avishai, S., Harry, P., Roybal, K.T. and Lanier, L.L. (2022) Differential IL-12 Signaling Induces Human Natural Killer Cell Activating Receptor-Mediated Ligand-Specific Expansion. Journal of Experimental Medicine, 219, e20212434.
https://doi.org/10.1084/jem.20212434
|
[8]
|
Ann, R., Brown, B.S., Stofega, M., et al. (2022) Targeting IRAK3 for Degradation to Enhance IL-12 Pro-Inflammatory Cytokine Production. ACS Chemical Biology, 17, 1315-1320.
https://doi.org/10.1021/acschembio.2c00037
|
[9]
|
Viola, N.T., Glassbrook, J.E., Kalluri, J.R., et al. (2022) Evalua-tion of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses. Frontiers in Micro-biology, 13, Article 870110.
https://doi.org/10.3389/fimmu.2022.870110
|
[10]
|
Mahung, C., Stepp, W.H., Long, C., et al. (2022) Early expres-sion of IL-10, IL-12, ARG1 and NOS2 Genes in Peripheral Blood Mononuclear Cells Synergistically Correlate with Pa-tient Outcome after Burn Injury. Journal of Trauma and Acute Care Surgery, 93, 702-711. https://doi.org/10.1097/TA.0000000000003602
|
[11]
|
Kawamoto-Miyamoto, N., Hosoda, H., Miyoshi, K. and Nomoto, K. (2022) Glutamate in the Medium of Lactiplantibacillus plantarum FL-664 Affects the Production of IL-12(p40) on Murine Spleen Cells. Bioscience, Biotechnology, and Biochemistry, 86, 535-542. https://doi.org/10.1093/bbb/zbac006
|
[12]
|
Merkley, S.D., Goodfellow, S.M., Guo, Y., Wilton, Z.E.R., Byrum, J.R., Schwalm, K.C., Dinwiddie, D.L., Gullapalli, R.R., Deretic, V., Jimenez Hernandez, A., Bradfute, S.B., Julie, I.G. and Castillo, E.F. (2022) Non-Autophagy Role of Atg5 and NBR1 in Unconventional Secretion of IL-12 Prevents Gut Dysbiosis and Inflammation. Journal of Crohn’s and Colitis, 16, 259-274. https://doi.org/10.1093/ecco-jcc/jjab144
|
[13]
|
Vincken, N.L.A., Welsing, P.M.J., Silva-Cardoso, S.C., et al. (2022) Suppression of IL-12/IL-23 p40 Subunit in the Skin and Blood of Psoriasis Patients by Tofacitinib Is Dependent on Ac-tive Interferon-γ Signaling in Dendritic Cells: Implications for the Treatment Of Psoriasis and Interferon-Driven Diseases. Experimental Dermatology, 31, 962-969.
https://doi.org/10.1111/exd.14566
|
[14]
|
Floss, D.M., Schröder, J., Franke, M. and Scheller, J. (2015) Insights into IL-23 Biology: From Structure to Function. Cytokine & Growth Factor Reviews, 26, 569-78. https://doi.org/10.1016/j.cytogfr.2015.07.005
|
[15]
|
Yawalkar, N., Tscharner, G.G., Hunger, R.E. and Hassan, A.S. (2009) Increased Expression of IL-12p70 and IL-23 by Multiple Dendritic Cell and Macrophage Subsets in Plaque Pso-riasis. Journal of Dermatological Science, 54, 99-105.
https://doi.org/10.1016/j.jdermsci.2009.01.003
|
[16]
|
Nograles, K.E., Brasington, R.D. and Bowcock, A.M. (2009) New Insights into the Pathogenesis and Genetics of Psoriatic Arthritis. Nature Clinical Practice Rheumatology, 5, 83-91. https://doi.org/10.1016/j.jdermsci.2009.01.003
|
[17]
|
Schurich, A., Raine, C., Morris, V. and Ciurtin, C. (2018) The Role of IL-12/23 in T Cell-Related Chronic Inflammation: Implications of Immunodeficiency and Therapeutic Blockade. Rheumatology, 57, 246-254.
https://doi.org/10.1093/rheumatology/kex186
|
[18]
|
Morelli, M., Galluzzo, M., Scarponi, C., et al. (2022) Allelic Variants of HLA-C Upstream Region, PSORS1C3, MICA, TNFA and Genes Involved in Epidermal Homeostasis and Barrier Function Influence the Clinical Response to Anti-IL-12/IL-23 Treatment of Patients with Psoriasis. Vaccines, 10, Article 1977.
https://doi.org/10.3390/vaccines10111977
|
[19]
|
Whitley, S., Li, M., Kashem, S.W., et al. (2022) Local IL-23 Is Required for Proliferation and Retention of Skin-Resident Memory T17 Cells. Science Immunology, 7, eabq3254.
https://doi.org/10.1126/sciimmunol.abq3254
|
[20]
|
Xiong, D.-K., Shi, X., Han, M.-M., et al. (2022) The Regulatory Mechanism and Potential Application of IL-23 in Autoimmune Diseases. Frontiers in Pharmacology, 13, Article 982238. https://doi.org/10.3389/fphar.2022.982238
|
[21]
|
Noack, M. and Miossec, P. (2022) Synoviocytes and Skin Fibro-blasts Show Opposite Effects on IL-23 Production and IL-23 Receptor Expression during Cell Interactions with Immune Cells. Arthritis Research & Therapy, 24, Article No. 220. https://doi.org/10.1186/s13075-022-02904-9
|
[22]
|
张洋洋, 王刚. IL-12/23抑制剂乌司奴单抗在银屑病治疗中的应用[J]. 中国皮肤性病学杂志, 2020, 34(4): 454-457.
https://doi.org/10.13735/j.cjdv.1001-7089.201906105
|
[23]
|
Koutruba, N., Emer, J. and Lebwohl, M. (2010) Review of Ustekinumab, an Interleukin-12 and Interleukin-23 Inhibitor Used for the Treatment of Plaque Psoriasis. Therapeutics and Clinical Risk Management, 6, 123-141.
https://doi.org/10.2147/TCRM.S5599
|
[24]
|
Leonardi, C.L., Kimball, A.B., Papp, K.A., et al. (2008) Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 76-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 1). The Lancet, 371, 1665-1674. https://doi.org/10.1016/S0140-6736(08)60725-4
|
[25]
|
Papp, K.A., Langley, R.G., Lebwohl, M., et al. (2008) Effi-cacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). The Lancet, 371, 1675-1684. https://doi.org/10.1016/S0140-6736(08)60726-6
|
[26]
|
Zhu, X., Zheng, M., Song, M., et al. (2013) Efficacy and Safety of Ustekinumab in Chinese Patients with Moderate to Severe Plaque-Type Psoriasis: Results from a Phase 3 Clin-ical Trial (LOTUS). Journal of Drugs in Dermatology, 12, 166-174.
|
[27]
|
Griffiths, C.E.M., Strober, B.E., van de Kerkhof, P., et al. (2010) Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis. The New Eng-land Journal of Medicine, 362, 118-128.
https://doi.org/10.1056/NEJMoa0810652
|
[28]
|
Rich, P., Bourcier, M., Sofen, H., Fakharzadeh, S., Wasfi, Y., Wang, Y., Kerkmann, U. Ghislain, P.-D., Poulin, Y., on Behalf of the PHOENIX 1 Investigators (2014) Ustekinumab Im-proves Nail Disease in Patients with Moderate-to-Severe Psoriasis: Results from PHOENIX 1. British Journal of Der-matology, 170, 398-407. https://doi.org/10.1111/bjd.12632
|
[29]
|
McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., et al. (2013) Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 1 Year Results of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled PSUMMIT 1 Trial. The Lancet, 382, 780-789. https://doi.org/10.1016/S0140-6736(13)60594-2
|
[30]
|
Ritchlin, C., Rahman, P., Kavanaugh, A., et al. (2014) Effi-cacy and Safety of the Anti-IL-12/23 p40 Monoclonal Antibody, Ustekinumab, in Patients with Active Psoriatic Arthritis Despite Conventional Non-Biological and Biological Anti-Tumour Necrosis Factor Therapy: 6-Month and 1-Year Re-sults of the Phase 3, Multicentre, Double-Blind, Placebo-Controlled, Randomised PSUMMIT 2 Trial. Annals of the Rheumatic Diseases, 73, 990-999.
https://doi.org/10.1136/annrheumdis-2013-204655
|
[31]
|
Facheris, P., Valenti, M., Pavia, G., Elena, G., Alessandra, N., Riccardo, G. and Antonio, C. (2020) Brodalumab: A New Way to Inhibit IL-17 in Psoriasis. Dermatologic Therapy, 33, e13403. https://doi.org/10.1111/dth.13403
|
[32]
|
Guo, X.M., Mao, X.R., Tian, D., et al. (2022) Cryptococcus neoformans Infection Induces IL-17 Production by Promoting STAT3 Phosphorylation in CD4+ T Cells. Frontiers in Immunology, 13, Article ID: 872286.
https://doi.org/10.3389/fimmu.2022.872286
|
[33]
|
Daudén, E., Castañeda, S., Suárez, C., et al. (2013) Clinical Practice Guideline for an Integrated Approach to Comorbidity in Patients with Psoriasis. Journal of the European Acad-emy of Dermatology and Venereology, 27, 1387-1404.
https://doi.org/10.1111/jdv.12024
|
[34]
|
Wilson, N.J., Boniface, K., Chan, J.R., et al. (2007) Development, Cytokine Profile and Function of Human Interleukin 17-Producing Helper T Cells. Nature Immunology, 8, 950-957. https://doi.org/10.1038/ni1497
|
[35]
|
Miossec, P. and Kolls, J.K. (2012) Targeting IL-17 and TH17 Cells in Chronic Inflammation. Nature Reviews Drug Discovery, 11, 763-776. https://doi.org/10.1038/nrd3794
|
[36]
|
Kryczek, I., Bruce, A.T., Gudjonsson, J.E., et al. (2008) Induction of IL-17+ T Cell Trafficking and Development by IFN-Gamma: Mechanism and Pathological Relevance in Psoriasis. The Journal of Immunology, 181, 4733-4741.
https://doi.org/10.4049/jimmunol.181.7.4733
|
[37]
|
Lin, A.M., Rubin, C.J., Khandpur, R., et al. (2011) Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis. The Journal of Immunology, 187, 490-500. https://doi.org/10.4049/jimmunol.1100123
|
[38]
|
Deodhar, A., Mease, P.J., McInnes, I.B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L. and Fox, T. (2019) Long-Term Safety of Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spon-dylitis: Integrated Pooled Clinical Trial and Post-Marketing Surveillance Data. Arthritis Research & Therapy, 21, Article No. 111. https://doi.org/10.1186/s13075-019-1882-2
|
[39]
|
Reich, K., Armstrong, A.W., Langley, R.G., et al. (2019) Guselkumab versus Secukinumab for the Treatment of Moderate-to-Severe Psoriasis (ECLIPSE): Results from a Phase 3, Randomised Controlled Trial. The Lancet, 394, 831-839.
https://doi.org/10.1016/S0140-6736(19)31773-8
|
[40]
|
Blauvelt, A. (2016) Safety of Secukinumab in the Treatment of Psoriasis. Expert Opinion on Drug Safety, 15, 1413-1420. https://doi.org/10.1080/14740338.2016.1221923
|
[41]
|
Wang, H.N. and Huang, Y.H. (2020) Changes in Metabolic Parameters in Psoriatic Patients Treated with Secukinumab. Therapeutic Advances in Chronic Disease, 11. https://doi.org/10.1177/2040622320944777
|
[42]
|
Goldberg, I.M., Brooks, J.K., Ghita, I., et al. (2022) Oral and Cutaneous Pemphigus Vulgaris: An Atypical Clinical Presentation. General Dentistry, 70, 22-26.
|
[43]
|
Singh, P.K., Das, S., Rai, G., et al. (2022) A Snapshot of T Cell Subset Cytokines in Pemphigus Vulgaris: A Cross-Sectional Study. Cu-reus, 14, e29890. https://doi.org/10.7759/cureus.29890
|
[44]
|
Alshami, M.L., Aswad, F. and Abdullah, B. (2022) A Clinical and Demographic Analysis of Oral Pemphigus Vulgaris: A Retrospective Cross-Sectional Study from 2001 to 2021. Health Science Reports, 5, e832.
https://doi.org/10.1002/hsr2.832
|
[45]
|
Hudemann, C., Exner, Y., Pollmann, R., et al. (2023) IgG against the Mem-brane-Proximal Portion of the Desmoglein 3 Ectodomain Induces Loss of Keratinocyte Adhesion, a Hallmark in Pem-phigus Vulgaris. Journal of Investigative Dermatology, 143, 254-263. https://doi.org/10.1016/j.jid.2022.07.030
|
[46]
|
Lin, X., Chen, M., Li, X., et al. (2022) Low SOCS3 Expression in CD4+ T Cells from Pemphigus Vulgaris Patients Enhanced Th1- and Th17-Cell Differentiation and Exacerbated Acan-tholysis via STAT Activation. Molecular Immunology, 150, 114-125. https://doi.org/10.1016/j.molimm.2022.08.007
|
[47]
|
Hutchison, D.M., Hosking, A.-M., Hong, E.M., et al. (2022) Mitochondrial Autoantibodies and the Role of Apoptosis in Pemphigus Vulgaris. Antibodies, 11, Article 55. https://doi.org/10.3390/antib11030055
|
[48]
|
Hebert, V. and Joly, P. (2018) Rituximab in Pemphigus. Immunother-apy, 10, 27-37.
https://doi.org/10.2217/imt-2017-0104
|
[49]
|
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., et al. (2017) First-Line Rituximab Combined with Short-Term Prednisone versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicentre, Parallel-Group, Open-Label Randomised Trial. The Lancet, 389, 2031-2040. https://doi.org/10.1016/S0140-6736(17)30070-3
|
[50]
|
Tan-Lim, R. and Bystryn, J.C. (1990) Effect of Plasmapher-esis Therapy on Circulating Levels of Pemphigus Antibodies. Journal of the American Academy of Dermatology, 22, 35-40. https://doi.org/10.1016/0190-9622(90)70004-2
|